Liquid Biopsies and Molecular Testing in NSCLC

Video
Nicholas Rohs, MD, of Mount Sinai

Nicholas C. Rohs, MD, Isabel Preeshagul, DO, MBS, and Joshua K. Sabari, MD, discuss the significance of molecular testing in clinical practice and the evolution of liquid biopsies in lung cancer treatment.

Nicholas C. Rohs, MD, Isabel Preeshagul, DO, MBS, and Joshua K. Sabari, MD, discuss the significance of molecular testing in clinical practice and the evolution of liquid biopsies in lung cancer treatment.

The discussion was held during an episode of Thoracic Night Live.

Related Videos
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
Sundar Jagannath, MBBS
Stephen V. Liu, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Manmeet Singh Ahluwalia, MD
Related Content
Shun Lu, MD, PhD

Repotrectinib Receives NMPA Approval in China for ROS1+ NSCLC

May 13th 2024
Article
Matthew Galsky, MD

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced/Metastatic Urothelial Carcinoma

February 12th 2024
Podcast
Lung Cancer

Nivolumab/Chemoradiotherapy Regimen Misses PFS End Point in Unresectable, Locally Advanced NSCLC

May 10th 2024
Article
Hari B. Keshava, MD

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

October 23rd 2023
Podcast
Andrew Joe, MD

FDA Grants Priority Review to Zenocutuzumab BLA for NRG1+ NSCLC and Pancreatic Cancer

May 7th 2024
Article
Margie Clapper, PhD, Co-Leader, Cancer Prevention and Control Research Program, Samuel M.V. Hamilton Chair in Cancer Prevention, Fox Chase Cancer Center

Fox Chase Cancer Center Researchers Show Estrogen Metabolites Contribute to Development of Lung Cancer Among People Who Never Smoked

May 2nd 2024
Article